Galapagos is developing a first in class molecule to treat auto-immune diseases like rheumatoid arthritis and Crohn’s disease. This new mode of action filgotinib acts on the target JAK1. Galapagos identified JAK1 as a target for auto-immune diseases in 2004, and subsequently developed candidate drug ‘filgotinib’ acting against this target. Filgotinib has been used by over 900 patient in phase 2 studies and showed excellent safety and efficacy. This potentially best treatment opportunity in rheumatoid arthritis and Crohn’s disease is now in phase 3 development. The story of 13 years R&D, from finding JAK1 to filgotinib, with its ups and downs, its opportunities and challenges will be discussed as a case study for true innovation in developing medicines that make a difference to patients.
Business model Galapagos
Onno van de Stolpe
Onno van de Stolpe founded Galapagos in 1999 and has served as Chief Executive Officer and a member of the board of directors from 1999 to the present. From 1998 to 1999, he was the Managing Director of Genomics at IntroGene B.V. (later Crucell N.V., which was acquired by Johnson & Johnson Services, Inc. in 2011). Prior to joining IntroGene in 1998, he was Managing Director of Molecular Probes Europe B.V. He established this European headquarters after joining Molecular Probes, Inc. in the United States. Previously, he worked for The Netherlands Foreign Investment Agency in California, where he was responsible for recruiting biotechnology and medical device companies to locate in The Netherlands. Mr. Van de Stolpe started his career as Manager of Business Development at MOGEN International N.V. in Leiden. He received an MSc degree from Wageningen University. Mr. Van de Stolpe currently also serves as a member of the supervisory board of the Stichting Institute for Human Organ and Disease Model Technologies and has previously served as a member of the board of directors of DCPrime B.V.
Jumpstart your career
Join BioBusiness Summer School to jumpstart your career in Life Sciences by gaining knowledge of business aspects such as product development, IPR, finance and business models. The next edition of the summer school will be organised from 25-29 June 2018 in Amsterdam, Leiden and Utrecht, the Netherlands. Register now!
The BioBusiness Summer School is a programme tailored to bridge the gap. By immersing yourself in the business aspects of Life Sciences during this programme, you will learn the basic knowledge of BioBusiness, gain insight in the world of Life Sciences companies, meet leading business leaders and increase your international network.